Compare FCN & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCN | COGT |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 6.0B |
| IPO Year | 1996 | 2018 |
| Metric | FCN | COGT |
|---|---|---|
| Price | $174.90 | $32.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $165.00 | $36.21 |
| AVG Volume (30 Days) | 492.6K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.51 | N/A |
| EPS | ★ 8.24 | N/A |
| Revenue | ★ $3,788,857,000.00 | $7,871,000.00 |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $7.10 | $1,581.80 |
| P/E Ratio | $20.47 | ★ N/A |
| Revenue Growth | ★ 2.44 | N/A |
| 52 Week Low | $149.31 | $3.72 |
| 52 Week High | $183.72 | $43.73 |
| Indicator | FCN | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 63.60 | 35.48 |
| Support Level | $174.66 | $33.27 |
| Resistance Level | $180.44 | $41.02 |
| Average True Range (ATR) | 4.79 | 1.79 |
| MACD | 1.31 | -0.37 |
| Stochastic Oscillator | 86.91 | 11.73 |
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.